Home › Research › Treatments
Neurodegeneration in Alzheimer’s Disease: Integrating Mechanism with Translational Therapeutic Strategies
Ejaz Samiul Hoque, Deepak Kumar Jha, Jaya Saha. Current Journal of Applied Science and Technology, 2026-04-24
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer disease (AD) is a progressive neurodegenerative disease and the most common cause of dementia in the world, which has a gradual deterioration of memory, thinking and autonomy. The AD pathogenesis is a multifaceted and intricate interaction between molecular/cellular processes like amyloid-ß (Aß) aggregation, tau hyperphosphorylation, neuroinflammation, synaptic dysfunction, vascular changes, and genetic predisposing factors (APOE 4 allele). The amyloid cascade proposal suggests that when there is an anomaly in the handling of amyloid precursor protein, it will cause aggregation of Aß, which will culminate into the development of toxic oligomers and as well as extracellular plaques, and the eventual destruction of neurons. Tau pathology is also associated with a further role in neurodegeneration by causing intracellular neurofibrillary tangles and impairment of transport via axons. The studies on biomarkers obtained in recent years, such as cerebrospinal fluid biomarkers, plasma phosphorylated tau, and neuroimaging, such as structural MRI, have greatly augmented the exquisite rooting of the disease by detecting and classifying in its initial phases using AT(N) biomarker framework. Symbolic treatment has changed to disease-modifying treatment designed to inhibit the cholinergic system, glutamatergic system, anti-amyloid monoclonal antibodies, anti-tau therapy, and neuroinflammatory and metabolic dysfunction modulators. New technologies such as gene-editing, stem cell-therapy, exosome-therapy, digital-neuromodulation technologies etc also add to the translational therapeutic landscape. Moreover, multidomain lifestyle intervention, cognitive engagement, and any preventive approach to vascular risk management can be vital to eliminate the risk and development of diseases. Irrespective of these developments, there are still major challenges in translational research, such as heterogeneity of diseases, evaluation limitations of preclinical models, and inability to intervene clinically promptly. Precision medicine methods with multimodal biomarkers, early-stage diagnostics, and combination therapy should be considered in the future research to enhance the clinical outcomes and decrease the worldwide Alzheimer disease burden.
What this study adds
Evidence grade: Low
This review describes mechanisms proposed for Alzheimer's disease, including amyloid-beta aggregation, tau hyperphosphorylation, neuroinflammation, and genetic factors such as APOE 4. It mentions that treatment has moved toward disease-modifying approaches such as anti-amyloid monoclonal antibodies and anti-tau therapy, but reports no new trial results or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hoque, E. S., Jha, D. K., & Saha, J. (2026). Neurodegeneration in Alzheimer’s Disease: Integrating Mechanism with Translational Therapeutic Strategies. Current Journal of Applied Science and Technology. https://doi.org/10.9734/cjast/2026/v45i54693
Vancouver
Hoque ES, Jha DK, Saha J. Neurodegeneration in Alzheimer’s Disease: Integrating Mechanism with Translational Therapeutic Strategies. Current Journal of Applied Science and Technology. 2026. doi:10.9734/cjast/2026/v45i54693.
BibTeX
@article{hoque2026-bafed243,
author = {Hoque, Ejaz Samiul and Jha, Deepak Kumar and Saha, Jaya},
title = {{Neurodegeneration in Alzheimer’s Disease: Integrating Mechanism with Translational Therapeutic Strategies}},
journal = {Current Journal of Applied Science and Technology},
year = {2026},
doi = {10.9734/cjast/2026/v45i54693},
url = {https://doi.org/10.9734/cjast/2026/v45i54693}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The amyloid cascade proposal suggests that when there is an anomaly in the handling of amyloid precursor protein, it will cause aggregation of Aß, which will culminate into the development of toxic oligomers and as well as extracellular plaques, and the eventual destruction of neurons.
- Tau pathology is also associated with a further role in neurodegeneration by causing intracellular neurofibrillary tangles and impairment of transport via axons.
Why it matters
This review describes mechanisms proposed for Alzheimer's disease, including amyloid-beta aggregation, tau hyperphosphorylation, neuroinflammation, and genetic factors such as APOE 4. It mentions that treatment has moved toward disease-modifying approaches such as anti-amyloid monoclonal antibodies and anti-tau therapy, but reports no new trial results or cure.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 27/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 26 of the 96 points we could judge it on, which is 27 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current Journal of Applied Science and Technology) |
| Journal's citation record | 0 / 4 | Current Journal of Applied Science and Technology: journal h-index 25 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Jaya Saha holds only 7 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Government of Karnataka: institution h-index 90 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 26 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 26 of the 96 points we could judge it on is 27 out of 100. |
| Total | 27 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.9734/cjast/2026/v45i54693
- Original source →
- Free full text: Current Journal of Applied Science and Technology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also in Treatments
194 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.